Literature DB >> 18544625

The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.

Mishaela R Rubin1, John P Bilezikian, Donald J McMahon, Thomas Jacobs, Elizabeth Shane, Ethel Siris, Julia Udesky, Shonni J Silverberg.   

Abstract

CONTEXT: Primary hyperparathyroidism (PHPT) often presents without classical symptoms such as overt skeletal disease or nephrolithiasis. We previously reported that calciotropic indices and bone mineral density (BMD) are stable in untreated patients for up to a decade, whereas after parathyroidectomy, normalization of biochemistries and increases in BMD ensue.
OBJECTIVE: The objective of the study was to provide additional insights in patients with and without surgery for up to 15 yr.
DESIGN: The study had an observational design.
SETTING: The setting was a referral center. PATIENTS: Patients included 116 patients (25 men, 91 women); 99 (85%) were asymptomatic. INTERVENTION: Fifty-nine patients (51%) underwent parathyroidectomy and 57 patients were followed up without surgery. MAIN OUTCOME MEASURE: BMD was measured.
RESULTS: Lumbar spine BMD remained stable for 15 yr. However, BMD started to fall at cortical sites even before 10 yr, ultimately decreasing by 10 +/- 3% (mean +/- sem; P < 0.05) at the femoral neck, and 35 +/- 5%; P < 0.05 at the distal radius, in the few patients observed for 15 yr. Thirty-seven percent of asymptomatic patients showed disease progression (one or more new guidelines for surgery) at any time point over the 15 yr. Meeting surgical criteria at baseline did not predict who would have progressive disease. BMD increases in patients who underwent surgery were sustained for the entire 15 yr.
CONCLUSIONS: Parathyroidectomy led to normalization of biochemical indices and sustained increases in BMD. Without surgery, PHPT progressed in one third of individuals over 15 yr; meeting surgical criteria at the outset did not predict this progression. Cortical bone density decreased in the majority of subjects with additional observation time points and long-term follow-up. These results raise questions regarding how long patients with PHPT should be followed up without intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544625      PMCID: PMC2567863          DOI: 10.1210/jc.2007-1215

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  37 in total

Review 1.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Authors:  John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

Review 2.  Bone strength in primary hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 3.  Clinical practice. Asymptomatic primary hyperparathyroidism.

Authors:  John P Bilezikian; Shonni J Silverberg
Journal:  N Engl J Med       Date:  2004-04-22       Impact factor: 91.245

4.  Bone mineral content in patients with primary hyperparathyroidism without radiological evidence of skeletal changes.

Authors:  N Dalén; B Hjern
Journal:  Acta Endocrinol (Copenh)       Date:  1974-02

5.  Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism.

Authors:  P Vestergaard; C L Mollerup; V G Frøkjaer; P Christiansen; M Blichert-Toft; L Mosekilde
Journal:  BMJ       Date:  2000-09-09

6.  New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging.

Authors:  Paul Roschger; David W Dempster; Hua Zhou; Eleftherios P Paschalis; Shonni J Silverberg; Elisabeth Shane; John P Bilezikian; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2007-05       Impact factor: 6.741

7.  Forearm bone density in primary hyperparathyroidism: long-term follow-up with and without parathyroidectomy.

Authors:  D Sudhaker Rao; Elizabeth A Wallace; Rosella F Antonelli; Gary B Talpos; Mohammed R Ansari; Gordon Jacobsen; George W Divine; A Michael Parfitt
Journal:  Clin Endocrinol (Oxf)       Date:  2003-03       Impact factor: 3.478

8.  Bone loss and bone size after menopause.

Authors:  Henrik G Ahlborg; Olof Johnell; Charles H Turner; Gunnar Rannevik; Magnus K Karlsson
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

9.  "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease.

Authors:  Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

10.  Retrospective evaluation and adjustment of dual energy X-ray absorptiometry measurements for bone mineral density research studies.

Authors:  Zixing Fang; Jo Anne Smith; Alison Kleppinger; Susan T Reisine; Denise Emerson; Martin Kulldorff
Journal:  J Clin Densitom       Date:  2002       Impact factor: 2.963

View more
  124 in total

Review 1.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

2.  Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by G-SPECT myocardial perfusion imaging.

Authors:  Cecilia Marini; Massimo Giusti; Riccardo Armonino; Giorgio Ghigliotti; GianPaolo Bezante; Lara Vera; Silvia Morbelli; Elena Pomposelli; Michela Massollo; Patrizia Gandolfo; Francesco Minuto; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-04       Impact factor: 9.236

Review 3.  [Intraoperative parathyroid hormone determination for primary hyperparathyroidism].

Authors:  K Lorenz; H Dralle
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

4.  Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism.

Authors:  D Han; S Trooskin; X Wang
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

5.  Occult urolithiasis in asymptomatic primary hyperparathyroidism.

Authors:  Yu-Kwang Donovan Tay; Minghao Liu; Leonardo Bandeira; Mariana Bucovsky; James A Lee; Shonni J Silverberg; Marcella D Walker
Journal:  Endocr Res       Date:  2018-02-05       Impact factor: 1.720

6.  Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology.

Authors:  Cristiana Cipriani; Federica Biamonte; Aline G Costa; Chiyuan Zhang; Piergianni Biondi; Daniele Diacinti; Jessica Pepe; Sara Piemonte; Alfredo Scillitani; Salvatore Minisola; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2015-02-03       Impact factor: 5.958

7.  Identification and functional analysis of a novel CaSR mutation in a family with familial hypocalciuric hypercalcemia.

Authors:  Eun Sook Kim; Su Yeon Kim; Ji Young Lee; Je Ho Han; Tae Seo Sohn; Hyun Shik Son; Sung-Dae Moon
Journal:  J Bone Miner Metab       Date:  2015-09-19       Impact factor: 2.626

8.  Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism.

Authors:  Cristiana Cipriani; Alice Abraham; Barbara C Silva; Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Chengchen Zhang; Didier Hans; Shonni J Silverberg; John P Bilezikian
Journal:  Endocrine       Date:  2016-10-18       Impact factor: 3.633

9.  Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women.

Authors:  Emily M Stein; Barbara C Silva; Stephanie Boutroy; Bin Zhou; Ji Wang; Julia Udesky; Chiyuan Zhang; Donald J McMahon; Megan Romano; Elzbieta Dworakowski; Aline G Costa; Natalie Cusano; Dinaz Irani; Serge Cremers; Elizabeth Shane; X Edward Guo; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

Review 10.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.